Clearmind Medicine (CMND) announced notice of publication by the China National Intellectual Property Administration, referring to the Company’s proprietary non hallucinogenic compound, 5-methoxy-2-aminoindane, or MEAI, for the treatment of depression. According to the World Health Organization, major depressive disorder affects more than 280M people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available. Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Psychedelic: Compass Pathways, GH Research report Q3 earnings
- Clearmind Medicine files patent application in South Korea
- Clearmind Medicine announces publication of U.S. patent application
- Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration